ERDOĞAN, A. P. Et Al. 2022. Could the Inflammatory Prognostic Index Predict the Efficacy of Regorafenib in Patients with Metastatic Colorectal Cancer?. Journal of Gastrointestinal Cancer , vol.53, no.1 , 45-51.

ERDOĞAN, A. P., EKİNCİ, F., Karabaş, A., Balçık, O. Y., Barutça, S., & Dirican, A., (2022). Could the Inflammatory Prognostic Index Predict the Efficacy of Regorafenib in Patients with Metastatic Colorectal Cancer?. Journal of Gastrointestinal Cancer , vol.53, no.1, 45-51.

ERDOĞAN, ATİKE Et Al. "Could the Inflammatory Prognostic Index Predict the Efficacy of Regorafenib in Patients with Metastatic Colorectal Cancer?," Journal of Gastrointestinal Cancer , vol.53, no.1, 45-51, 2022

ERDOĞAN, ATİKE P. Et Al. "Could the Inflammatory Prognostic Index Predict the Efficacy of Regorafenib in Patients with Metastatic Colorectal Cancer?." Journal of Gastrointestinal Cancer , vol.53, no.1, pp.45-51, 2022

ERDOĞAN, A. P. Et Al. (2022) . "Could the Inflammatory Prognostic Index Predict the Efficacy of Regorafenib in Patients with Metastatic Colorectal Cancer?." Journal of Gastrointestinal Cancer , vol.53, no.1, pp.45-51.

@article{article, author={ATİKE PINAR ERDOĞAN Et Al. }, title={Could the Inflammatory Prognostic Index Predict the Efficacy of Regorafenib in Patients with Metastatic Colorectal Cancer?}, journal={Journal of Gastrointestinal Cancer}, year=2022, pages={45-51} }